Repligen Stock In Shambles: Down -19% With 6-Day Losing Streak
Repligen (RGEN) – a developer of bioprocessing technologies and Protein A ligands – hit a 6-day losing streak, with cumulative losses over this period amounting to -19%. The company’s market cap has crashed by about $1.3 Bil over the last 6 days and currently stands at $5.8 Bil.
Is this an opportunity or a trap? There are only a couple of things to fear in RGEN stock given its overall Strong operating performance and financial condition. But given its Very High valuation, the stock appears Relatively Expensive (For details, see Buy or Sell RGEN).
But here is the interesting part. You are reading about this -19% move after it happened. The market has already priced in the news. To manage individual stock risk before the headlines, you need predictive signals, not notifications. High Quality Portfolio has a risk model designed to manage stock-specific drawdowns better.
Returns vs S&P 500
- MU Stock: History Signals A Rebound After 13% Drop
- Anthropic At $1 Trillion May Actually Be Cheap
- How META Stock Rises To $1,000
- Get Paid 8.3% to Buy SPGI at a 30% Discount – Here’s How
- Abercrombie & Fitch Stock: Strong Cash Flow Poised for a Re-Rating?
- 5 Catalysts to Monitor Over In The Next 2 Quarters For META Stock
The following table summarizes the return for RGEN stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | RGEN | S&P 500 |
|---|---|---|
| 1D | -0.5% | -1.2% |
| 6D (Current Streak) | -18.6% | 1.0% |
| 1M (21D) | -19.1% | 5.2% |
| 3M (63D) | -24.6% | 8.4% |
| YTD 2026 | -37.2% | 8.2% |
| 2025 | 13.8% | 16.4% |
| 2024 | -19.9% | 23.3% |
| 2023 | 6.2% | 24.2% |
Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: RGEN Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 29 S&P constituents with 3 days or more of consecutive gains and 84 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 2 | 44 |
| 4D | 7 | 14 |
| 5D | 13 | 9 |
| 6D | 4 | 10 |
| 7D or more | 3 | 7 |
| Total >=3 D | 29 | 84 |
Key Financials for Repligen (RGEN)
Last 2 Fiscal Years:
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenues | $634.4 Mil | $738.3 Mil |
| Operating Income | $-31.9 Mil | $41.6 Mil |
| Net Income | $-25.5 Mil | $48.9 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ4 | 2026 FQ1 |
|---|---|---|
| Revenues | $197.9 Mil | $194.3 Mil |
| Operating Income | $16.3 Mil | $17.3 Mil |
| Net Income | $13.3 Mil | $8.3 Mil |
The losing streak RGEN stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.